Mitochondrial Dysfunction, Depleted Purinergic Signaling, and Defective T Cell Vigilance and Immune Defense

Carola Lederose,1 Yi Bao,1 Stephan Lederose,1 Tobias Woehrle,1,6 Maria Heinisch,1 Linda Yip,6,5 Jingping Zhang,1 Simon C. Robson,2 Nathan I. Shapiro,3 and Wolfgang G. Junger1,4,7

Departments of 1Surgery, 2Medicine, and 3Emergency Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; 4Department of Surgery, University of California, San Diego, and 5Department of Medicine, Division of Immunology and Rheumatology, Stanford University, California; 6Department of Anesthesiology, Ludwig-Maximilian University of Munich, Germany; and 7Ludwig Boltzmann Institute for Traumatology, Vienna, Austria

T cell suppression in sepsis is a well-known phenomenon; however, the underlying mechanisms are not fully understood. Previous studies have shown that T cell stimulation up-regulates mitochondrial adenosine triphosphate (ATP) production to fuel purinergic signaling mechanisms necessary for adequate T cell responses. Here we show that basal mitochondrial ATP production, ATP release, and stimulation of P2X1 receptors represent a standby purinergic signaling mechanism that is necessary for antigen recognition. Inhibition of this process impairs T cell vigilance and the ability of T cells to trigger T cell activation, up-regulate mitochondrial ATP production, and stimulate P2X4 and P2X7 receptors that elicit interleukin 2 production and T cell proliferation. T cells of patients with sepsis lack this standby purinergic signaling system owing to defects in mitochondrial function, ATP release, and calcium signaling. These defects impair antigen recognition and T cell function and are correlated with sepsis severity. Pharmacological targeting of these defects may improve T cell function and reduce the risk of sepsis.

Keywords. mitochondrial dysfunction; purinergic signaling; sepsis; T cell suppression.

Sepsis is a leading cause of death worldwide, with mortality rates ranging from 20% to 40% [1, 2]. Despite intensive research for several decades, our current understanding of the underlying mechanisms is limited and no effective treatments are available. This problem is underscored by the disappointing results of numerous clinical trials [1, 3]. Most conventional treatment strategies for sepsis in these trials have focused on blocking the cytokine-mediated hyperinflammatory response that causes systemic inflammation and multiorgan dysfunction. However, this initial hyperinflammatory response is offset by a protracted immunosuppressive phase with lethal consequences because it disables the cellular immune system that helps patients cope with primary and hospital-acquired infections that can progress to sepsis [4, 5].

This immunosuppressive phase is characterized by increased plasma levels of anti-inflammatory mediators such as interleukin 10 and by T cell suppression that impairs cytokine production and the proliferation of T cells in response to antigen stimulation [6–9]. The mechanisms involved in T cell suppression are unclear [10, 11]. It has only recently been recognized that T cell activation is accompanied by the release of cellular adenosine triphosphate (ATP) and autocrine feedback mechanisms involving purinergic receptors located on the cell surface of T cells [12–15]. Autocrine stimulation of P2X1, P2X4, and P2X7 receptors contributes to the influx of extracellular calcium ions (Ca2+), which is required for the initiation of effector functions such as interleukin 2 (IL-2) production and T cell proliferation [14, 15].

More recently, it was shown that mitochondria play a central role in these autocrine purinergic signaling mechanisms [12]. T cell stimulation rapidly increases mitochondrial activity and ATP formation and induces the translocation of mitochondria to the immunological synapse (IS) that T cells form with antigen-presenting cells. The ATP generated by mitochondria is released into the IS, where it drives autocrine purinergic signaling events that contribute to Ca2+ influx. In the current study, we investigated whether defects in these purinergic signaling processes are responsible for T cell suppression in sepsis.

We found that not only stimulated but also resting T cells require purinergic signaling mechanisms. In T cells from healthy subjects, basal mitochondrial activity and ATP release constitute a resting or basal purinergic signaling loop that maintains T cell vigilance and allows T cells to recognize and effectively respond to antigen stimulation. In patients with sepsis, this basal purinergic signaling mechanism is defective, resulting in impaired T cell vigilance, T cell suppression, and an inability of T cells to mount appropriate functional responses to infections.

MATERIALS AND METHODS

Reagents

Fluo-4-AM, tetramethylrhodamine ethyl ester (TMRE), dihydrorhodamine123 (DHR123) and MitoTracker Green-FM
were purchased from Molecular Probes (Life Technologies). Mouse anti–human CD4–allophycocyanin (APC) antibodies were obtained from Biolegend, and goat anti–mouse immunoglobulin G (IgG) Fc antibodies from Pierce (Thermo Scientific). Polystyrene particles (3.0–3.9 µm; Spherotech) or Dynabeads (Invitrogen; Life Technologies) coated with goat anti–mouse IgG antibodies were labeled with mouse anti–human CD3 and anti–human CD28 antibodies (BD Biosciences). Suramin, NF023, NF157, 5-BDBD, A438079, KN62, oxidized ATP (o-ATP), and NF340 were from Tocris Bioscience. All other reagents were from Sigma-Aldrich, unless otherwise stated.

**Patients**

Eligible patients included adults (>18 years) presenting to the emergency department of the Beth Israel Deaconess Medical Center (BIDMC) with a diagnosis of sepsis or septic shock based on published criteria [16]. Heparinized blood samples (4 mL) were obtained within 12 hours of sepsis diagnosis and before initiation of medical therapy with antibiotics or steroids as needed. Initial Sequential Organ Failure Assessment (SOFA) scores were calculated at admission [17]. Nonseptic patients presenting to the emergency department for benign complaints with noninfective causes and healthy volunteers served as control groups. Demographic patient characteristics are given in Supplementary Tables 1 and 2. All studies involving human subjects were approved by the Institutional Review Board of BIDMC, and written informed consent was obtained before blood samples were collected.

**Cells**

CD4+ T cells were purified from heparinized venous blood, as described elsewhere [18]. Leukocyte-rich plasma was obtained immediately after blood sampling by spontaneous sedimentation of red blood cells over Ficoll-PaqueTM PLUS (GE Healthcare) for 30 minutes at 37°C. The human T cell line Jurkat (clone E6-1; American Type Culture Collection) was cultured (4 mL) for 20 minutes was monitored by bright field imaging with the microscope system mentioned above.

**Assessment of Mitochondrial Membrane Potential, Reactive Oxygen Species Formation, and Mitochondrial Mass**

Mitochondrial membrane potential ($\Delta \Psi_m$) was assessed with TMRE, mitochondrial reactive oxygen species (ROS) formation with DHR123 and mitochondrial content with MitoTracker Green-FM. Cell preparations were diluted 1:10 in Hank’s buffered salt solution; incubated with TMRE (100 nmol/L), DHR123 (10 µmol/L), or MitoTracker Green-FM (1 µmol/L) and anti–CD4-APC monoclonal antibodies (1:1000) for 15 minutes at 37°C; and immediately analyzed using a BD FACS-Calibur flow cytometer (BD Biosciences). CD4+ T cells were identified by characteristic forward and side scattering and CD4 staining. In some experiments, cells were stimulated for 10 minutes with anti-CD3/CD28 antibody-coated polystyrene beads or anti-CD3/CD28 antibodies cross-linked by goat anti–mouse IgG. Jurkat cells were treated with inhibitors as described above, stained with TMRE (100 nM), and $\Delta \Psi_m$ was imaged using the microscope system described above.

**Intracellular Ca2+, ATP Release, and Messenger RNA Expression**

Cytosolic Ca2+ levels were measured in purified CD4+ T cells or enriched leukocytes using the Ca2+ indicator Fluo-4-AM, as described elsewhere [12]. In experiments with enriched leukocytes, CD4+ T cells were identified by forward or side scattering and CD4-APC staining. ATP measurements in cell culture supernatants and imaging of ATP release using the cell-surface-targeting fluorescent ATP probe 2'-2Zn(II) [20] were done as described elsewhere [12]. The expression of IL-2, P2X1, P2X4, and P2X7 messenger RNA (mRNA) was determined using quantitative polymerase chain reaction, as described elsewhere [14, 18].

**Statistical Analyses**

Unless otherwise stated, data are expressed as mean values (with standard deviations) from ≥3 independent experiments. Statistical analyses were performed using unpaired Student t tests for 2 groups or 1-way analysis of variance and post hoc Holm-Sidak test for multiple comparisons. Pearson analysis was used to test for correlation between parameters. Differences were considered statistically significant at $P < .05$. Fluorescence images were captured through a ×63 oil objective with a nominal aperture of 1.4 using fluorescein isothiocyanate (FITC) and tetrarhodamine isothiocyanate (TRITC) filter sets (Leica Microsystems) and Leica LAS microscope imaging software. Images were analyzed with ImageJ software (National Institutes of Health).
RESULTS

Purinergic Regulation of Ca2+ Signaling and Mitochondrial Activity in Stimulated T Cells

Autocrine purinergic signaling is an essential mechanism in T cell activation [13, 15, 21]. It was recently demonstrated that mitochondria accumulate at the IS of stimulated Jurkat T cells, where they generate large amounts of ATP that drives autocrine purinergic signaling processes [12]. ATP released at the IS stimulates P2X1 and P2X4 receptors that promote Ca2+ influx, which is essential for T cell activation [14, 22]. In the current study, we investigated whether these purinergic signaling processes also regulate mitochondrial ATP production. Stimulation of primary human CD4+ T cells by T cell receptor (TCR)/CD28 cross-linking induced a significant increase in cytosolic Ca2+ levels that was virtually completely blocked by pretreatment with the general P2 receptor inhibitor suramin (Figure 1A). These findings highlight the critical role of autocrine purinergic signaling in the regulation of Ca2+ signaling during T cell stimulation. To study whether purinergic signaling is also involved in mitochondrial activation, we cotransfected Jurkat cells with the Ca2+ biosensors G-GECO1.1 and mito-CAR-GECO1 that allow monitoring of real-time changes in cytosolic and mitochondrial Ca2+ levels after T cell stimulation (Supplementary Video 1). Using this approach, we found that suramin blocked the cytosolic Ca2+ response as well as mitochondrial Ca2+ uptake (Figure 1B).

Ca2+ uptake by mitochondria is known to promote mitochondrial ATP formation through oxidative phosphorylation [23]. Recently, it was demonstrated that autocrine purinergic signaling of stimulated T cells requires mitochondrial ATP production and that this process is paralleled by increases in mitochondrial membrane potential (ΔΨm) and formation of mitochondrial ROS [12]. Using CD4+ T cells, we found that suramin pretreatment blocked the increase in ΔΨm and ROS formation in response to T cell stimulation (Figure 1C). However, to our surprise, we noticed that suramin also significantly reduced baseline ΔΨm and ROS production in unstimulated CD4+ T cells (Figure 1C), which suggests that purinergic feedback mechanisms maintain basal mitochondrial activity in resting T cells.

Maintenance of T Cell Vigilance by Basal Purinergic Signaling

Using a novel membrane-anchoring fluorescent ATP sensor, 2′-2Zn(II) [20], it was shown that T cells release ATP at the IS [12]. In the current study, we found that resting T cells also release ATP from local hot spots associated with filopodia that seem to probe the extracellular environment for antigen-presenting cells (Figure 2A; Supplementary Video 2). On recognition of beads coated with anti-CD3/CD28 antibodies, ATP release intensified and concentrated at the IS (Figure 2A; Supplementary Video 3). Treating cells for 20 minutes with the mitochondrial inhibitor CCCP or with suramin impaired the interaction of cells with beads (Supplementary Video 4 and Supplementary Figure 1B). Suramin significantly reduced mitochondrial activity and the number of T cells binding to beads and responding with mitochondrial ATP production (Figure 2B and 2C; Supplementary Figure 1B and 1C). These findings indicate that T cells require purinergic signaling and mitochondrial ATP production to recognize antigens, form immune synapses, and to up-regulate mitochondrial activity. In support of this conclusion, we found that suramin or CCCP treatment abolished mitochondrial Ca2+ uptake and translocation of activated mitochondria to the IS (Supplementary Video 5). Taken together, these findings demonstrate that resting T cells have a basal purinergic signaling mechanism that maintains T cells at a level

Figure 1. Positive feedback through autocrine purinergic signaling stimulates calcium (Ca2+) signaling and mitochondrial activity during T cell activation. A. Purified CD4+ T cells (1 x 10^6/mL) were loaded with Fluo-4 and incubated for 10 minutes with or without (control) suramin (100 µmol/L). Then cells were stimulated by T cell receptor (TCR)/CD28 cross-linking, and Ca2+ signaling was analyzed with flow cytometry. Ionomycin was used to assess the maximum response. Representative dot plots of separate experiments (n = 3) with similar results are shown. B. Jurkat T cells transiently expressing the mitochondrial Ca2+ biosensor mito-CAR-GECO1 were treated or not treated (control) with suramin (100 µmol/L) for 20 minutes. Changes in mitochondrial Ca2+ after TCR stimulation were recorded using time-lapse fluorescence video microscopy and analyzed using National Institutes of Health ImageJ software. Results are shown as means (with standard deviations [SDs]) from different cells (n = 10–15) and are representative of separate experiments (n = 4) with similar results (see also Supplementary Video 1). C. Whole blood leukocytes were treated or not treated (control) with suramin (200 µmol/L) for 10 minutes and stimulated by TCR/CD28 cross-linking for another 10 minutes. Then cells were stained with DHR123 or tetramethylrhodamine ethyl ester (TMRE), and mitochondrial activation (DHR123) and changes in mitochondrial membrane potential were analyzed with flow cytometry. CD4+ T cells were identified using allophycocyanin–CD4 labeling; the percentages of cells with increased TMRE and DHR123 fluorescence are shown as means and SDs from separate experiments with cells from different donors (n = 3). *P < .05; †P < .01; ‡P < .001 [all Student t test]. Abbreviation: MFI, mean fluorescence intensity.
of vigilance that allows them to probe their extracellular environment and up-regulate mitochondrial activity and IS formation in response to antigen recognition.

**Control of Basal Mitochondrial Activity by Basal Purinergic Signaling**

It was previously demonstrated that mitochondria and pannexin-1 channels (panx1) contribute to the ATP release at the IS [12, 14]. Therefore, we tested whether mitochondria and panx1 are also involved in the purinergic signaling mechanism of resting T cells. Inhibition of panx1 or mitochondria with carbinoxolone (CBX) or CCCP decreased ATP release in resting Jurkat cells in a dose-dependent manner (Figure 3A). Inhibition of mitochondria and ATP release also reduced cytosolic Ca\(^{2+}\) levels in CD4\(^+\) T cells (Figure 3B). Likewise removal of extracellular ATP by apyrase or blocking of P2 receptor signaling with suramin decreased basal Ca\(^{2+}\) levels to a similar extent (Figure 3B). Because up-regulation of mitochondrial activity is part of the purinergic feedback cycle in stimulated T cells, as described above, we studied next how suramin affects ΔΨ\(_{m}\) in resting cells. Suramin markedly reduced ΔΨ\(_{m}\) in unstimulated Jurkat cells about as much as the uncoupling agent CCCP (Figure 3C and 3D; Supplementary Video 6). Together with the findings above, these results demonstrate that basal ATP release, basal purinergic signaling, and basal mitochondrial activity maintain Ca\(^{2+}\) homeostasis in resting T cells.

**Maintenance of T Cell Vigilance by P2X1 but Not P2X4 or P2X7 Receptors**

To further define the basal autocrine purinergic signaling mechanisms that maintain T cell vigilance, we studied how different P2 receptor antagonists affect ΔΨ\(_{m}\) and mitochondrial ATP production in resting CD4\(^+\) T cells. Similar to the results with Jurkat cells shown above, we found that the nonspecific P2 receptor antagonist suramin reduced both ΔΨ\(_{m}\) and mitochondrial ROS.
production in a dose-dependent manner (Figure 4A). Similar effects were observed with the P2X1 receptor antagonists NF023 and NF157 (Figure 4B and 4C) but not with the P2Y11 antagonist NF340. Previous work had shown that P2X1 along with P2X4 and P2X7 receptors contribute to cytosolic Ca\(^{2+}\) signaling in stimulated T cells [14, 15]. Our current studies indicate that neither P2X4 nor P2X7 receptors contribute to the basal purinergic signaling that maintains mitochondrial function in resting T cells. Neither inhibition of P2X4 receptors with 5-BDBD nor inhibition of P2X7 receptors with KN62 or A438079 reduced the mitochondrial activity in resting CD4\(^{+}\) T cells (Figure 4C).

**Basal Purinergic Signaling and Functional T cell Responses**

The findings described above demonstrate that basal autocrine purinergic signaling via P2X1 receptors maintains mitochondrial function and the immune vigilance of unstimulated T cells. In support of this notion, we found that inhibition of mitochondrial ATP production with CCCP, removal of released ATP with apyrase, or inhibition of P2X1 receptors with suramin or NF023, but not of P2X4 or P2X7 receptors with 5-BDBD or A438079, blocked \(\Delta \Psi\) in resting CD4\(^{+}\) T cells (Figure 5A).

The inhibition of purinergic signaling also decreased basal cytosolic Ca\(^{2+}\) levels and impaired Ca\(^{2+}\) signaling in response to TCR/CD28 stimulation (Figure 5B). Although the P2X7 receptor antagonists A438079 did not significantly affect basal cytosolic Ca\(^{2+}\) levels, it blocked Ca\(^{2+}\) signaling after TCR stimulation. Inhibition of purinergic signaling with either P2X1 (NF023) or P2X7 (A438079 or \(\alpha\)-ATP) receptor inhibitors reduced IL-2.
mRNA synthesis of stimulated T cells (Figure 5B and 5C). Taken together with previous reports [14, 15], these results indicate that there are 2 distinct autocrine purinergic signaling systems: one facilitating T cell vigilance through P2X1 receptors and a second one regulating functional T cell responses via P2X1, P2X4, and P2X7 receptors.

**Defective Basal Purinergic Signaling, T Cell Vigilance, and T Cell Function in Sepsis**

T cell suppression in sepsis is a well-known phenomenon [24], but its underlying mechanisms are unclear. We wondered whether sepsis impairs the basal purinergic signaling events that maintain T cell vigilance. To test this possibility, we assessed basal ΔΨ<sub>m</sub> and mitochondrial ROS production in CD4<sup>+</sup> T cells from patients admitted to the emergency department at BIDMC. We found that both mitochondrial parameters were markedly lower in cells from patients with sepsis than in healthy controls or patients without sepsis, whereas there were no significant differences in total mitochondrial content among these 3 cohorts (Figure 6A-C; Supplementary Figure 2A). Furthermore, alterations in P2X receptor expression levels did not seem to contribute to T cell suppression, because mRNA expression was either unchanged (P2X4, P2X7) or up-regulated (P2X1) in T cells of patients with sepsis compared with control cells (Supplementary Figure 2B). The decreased mitochondrial activity levels in T cells of septic patients were paralleled by significantly lower basal and stimulated Ca<sup>2+</sup> levels (Figure 7A).

These findings suggest that impaired basal mitochondrial function and purinergic signaling deplete the mechanism that maintains T cell vigilance and the ability of T cells to mount appropriate responses to antigen stimulation.

**Figure 5.** P2X1 receptors together with P2X7 receptors contribute to the functional responses of activated T cells. A, CD4<sup>+</sup> T cells were treated or not treated (control) for 20 minutes with carbonyl cyanide m-chlorophenylhydrazone (CCCP; 50 µmol/L), suramin (200 µmol/L), A438079 (10 µmol/L), suramin (200 µmol/L), S-BOBD (10 µmol/L), or A438079 (10 µmol/L), and mitochondrial membrane potential (ΔΨ<sub>m</sub>) was assessed with tetramethylrhodamine ethyl ester (TMRE) and flow cytometry; values are presented as means and standard deviations (SDs) (n = 3–5). *P < .05 (vs control; 1-way analysis of variance [ANOVA]). B, CD4<sup>+</sup> T cells were treated or not treated (control) with apyrase (20 U/mL), suramin (200 µmol/L), or A438079 (10 µmol/L) for 10 minutes and loaded with fluo-4; cytosolic calcium ion (Ca<sup>2+</sup>) levels were assessed before and 3 minutes after cell stimulation via T cell receptor (TCR)/CD28 cross-linking using flow cytometry. Values represent means and SDs of 3–6 experiments. *P < .05 (vs noninhibitor control; 1-way ANOVA). C, CD4<sup>+</sup> T cells were treated or not treated (control) for 10 minutes with the indicated concentrations of apyrase or suramin, the P2X1 receptor inhibitor NF023, or the P2X7 receptor inhibitor oxidized ATP (o-ATP). Then cells were stimulated via TCR/CD28 using anti-CD3/CD28 antibody–coated beads for 1 hour, and interleukin 2 (IL-2) messenger RNA (mRNA) expression was determined by means of quantitative polymerase chain reaction. Values represent means and SDs of 3 separate experiments with cells from different donors. *P < .05 (vs control).

**Figure 6.** Mitochondrial function is decreased in lymphocytes of septic patients. A–C, CD4<sup>+</sup> T cells of healthy subjects (n = 8–16) or patients admitted to the emergency department with sepsis (n = 9–14) or without sepsis (n = 7–10) were stained with tetramethylrhodamine ethyl ester (TMRE) to assess mitochondrial membrane potential (ΔΨ<sub>m</sub>) or with DHR123 to assess reactive oxygen species (ROS) formation as a measure of mitochondrial activity. Cells were analyzed with flow cytometry, and CD4<sup>+</sup> T cells were identified by forward/side scattering and CD4 staining. A, B, Representative histograms of CD4<sup>+</sup> T cells stained with TMRE (A) or DHR123 (B). C, TMRE mean fluorescence intensity (MFI) values or the percentage of DHR123-positive cells (as defined in B) among CD4<sup>+</sup> T cells derived from healthy subjects and patients with or without sepsis. *P < .05 (1-way analysis of variance).
The incidence of severe sepsis is higher in elderly individuals [26]. Subjects in both of our control groups were significantly younger than patients in the sepsis group. This limitation of our study should be addressed in future larger studies with age-matched control groups. However, we did not find that any of the parameters tested were significantly correlated with age. Instead, we found that defects in mitochondrial function and basal purinergic signaling strongly correlated with sepsis severity. However, additional studies with larger patient cohorts will be necessary to determine how these changes impact survival. Furthermore, although samples were obtained immediately after the diagnosis of sepsis and before the initiation of further medical treatment, we did not investigate how medications administered before sepsis was diagnosed might have influenced our results.
We conclude that defective mitochondrial function and basal purinergic signaling in sepsis result in T cell suppression [5,24,27]. Our findings are in agreement with other reports of depletion of cellular oxygen consumption and mitochondrial function in sepsis [28–33]. Previous studies have shown that sepsis dramatically depletes cytosolic Ca2+ levels of resting and stimulated T cells [34,35]. Our finding that mitochondrial function and purinergic signaling are closely linked to cellular Ca2+ homeostasis provides an explanation for those surprising findings.

Previous studies have also shown that the activation of IL-2 production and proliferation of T cells requires P2X1, P2X4, and P2X7 receptors [13–15]. In the current study, we found that, of these receptors, only P2X1 contributes to T cell vigilance. P2X1 receptors display strong affinity for ATP (100–700 nmol/L [36]), but considerably higher ATP concentrations are needed to stimulate P2X4 (micromolar [37]) and P2X7 receptors (>1 mmol/L [38,39]). Release of low amounts of ATP from resting T cells would therefore preferentially stimulate P2X1 receptors, whereas ATP concentrations high enough for P2X4 and P2X7 receptor stimulation require TCR/CD28 stimulation and up-regulated mitochondrial ATP production. Further studies applying genetic approaches such as receptor silencing will be needed to confirm our results and to dissect the specific roles of P2X receptor subtypes in the regulation of unstimulated and stimulated T cells.

Despite intensive research and numerous clinical trials during the last 2 decades, there has been little improvement in the treatment of sepsis. Therapeutic approaches targeting triggers of the hyperinflammatory phase have been explored but none of these approaches showed clinical efficacy in patients [3]. This has led to a reassessment of the pathology of sepsis [10,24]. Our current study defines a novel mechanism of T cell suppression, whereby mitochondrial dysfunction depletes purinergic signaling, disrupts Ca2+ homeostasis, and impairs the vigilance of T cells and their ability to mount functional responses to T cell stimulation. This new concept points to new strategies designed to improve T cell function and immune defense in septic patients. These strategies may include approaches to avoid mitochondrial dysfunction, to bolster ATP production by mitochondria, and to promote T cell function by enhancing purinergic feedback mechanisms in order to restore T cell vigilance and prevent immunosuppression in sepsis.

Potential conflicts of interest. All authors: No potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

Downloaded from https://academic.oup.com/jid/article-abstract/213/3/456/2459218 by guest on 19 February 2019